We’re at #SITC2019, sharing data from our SRF388 program today — a first-in-class, monoclonal antibody that blocks the immunoregulatory effects of IL-27 in immune cells & demonstrates preclinical in vivo antitumor activity. See our poster: https://t.co/ZBnb2LTJGW #IL27Insights